Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Iovance Biotherapeutics (IOVA) over the last 12 years, with Q3 2025 value amounting to -$78.7 million.

  • Iovance Biotherapeutics' Cash from Operations fell 3345.43% to -$78.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$323.2 million, marking a year-over-year increase of 1113.4%. This contributed to the annual value of -$353.0 million for FY2024, which is 243.77% up from last year.
  • Iovance Biotherapeutics' Cash from Operations amounted to -$78.7 million in Q3 2025, which was down 3345.43% from -$67.4 million recorded in Q2 2025.
  • Iovance Biotherapeutics' 5-year Cash from Operations high stood at -$59.0 million for Q3 2024, and its period low was -$122.3 million during Q1 2024.
  • Moreover, its 3-year median value for Cash from Operations was -$84.1 million (2023), whereas its average is -$87.7 million.
  • Within the past 5 years, the most significant YoY rise in Iovance Biotherapeutics' Cash from Operations was 3148.26% (2025), while the steepest drop was 3345.43% (2025).
  • Over the past 3 years, Iovance Biotherapeutics' Cash from Operations (Quarter) stood at -$84.0 million in 2023, then grew by 12.68% to -$73.3 million in 2024, then decreased by 7.34% to -$78.7 million in 2025.
  • Its Cash from Operations stands at -$78.7 million for Q3 2025, versus -$67.4 million for Q2 2025 and -$103.7 million for Q1 2025.